\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\begin{document}


\def\RunningAuthor{Dibya Jyoti Sharma et al.}
\firstPage{1815}
\articleType{Case Report}
\receivedDate{03 Nov 2020}
\acceptedDate{16 Dec 2020}
\revisedDate{12 Dec 2020}
\journalVolume{2020, 11 (SPL)}
\journalIssue{1}
\journalDoi{ijrps.v11iSPL1.4291}
\copyrightYear{2020}
\def\authorCount{4}
\def\affCount{3}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{Guillainbarr{\'e} Syndrome not responding to Remdesivir, Enoxaparin and High dose methylprednisolone in Patient with Covid 19 and eclampsia in Pregnancy: A case report}
\author{Dibya~Jyoti~Sharma\textsuperscript{*}\textsuperscript{1},  
            Aveenash~Pawar\textsuperscript{1},  
            Phulen~Sarma\textsuperscript{2}, 
            Gaurav~Muktesh\textsuperscript{3}~\\[5pt]{\textsuperscript{1}Department of General Medicine, Silchar Medical College and Hospital (SMCH), Assam, India}~\\{\textsuperscript{2}Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India}~\\{\textsuperscript{3}Department of Gastroenterology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India}}

\begin{abstract}
COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has protean manifestations. Nervous system involvement though uncommon in COVID-19 can present with debilitating manifestations like necrotising encephalopathy, myopathy, seizure, peripheral neuropathy and Guillain Barr{\'e} syndrome. In this case report, we report a case of 27 years old woman who presented to us with post partum eclampsia and developed acute flaccid quadriparesis 5 days after COVID-19 infection which was manifested as cough, anosmia and ageusia without fever. Patient developed dyspnoea followed by type 2 respiratory failure 8 days after hospitalization for which she was put into mechanical ventilation. She was treated with high dose Methylprednisolone and standard medical therapy. IVIG or plasmapheresis could not be given due to non-availability. Patient expired in ICU after 18 days of hospital admission. SARS-COV-2 mainly infects the respiratory system of the body but it may have the neurotropic capacity and its ability to produce immune dysregulation can produce a cascade of inflammatory reactions in the nervous system. Guillain Barr{\'e} syndrome is a heterogeneous disorder triggered by many viral infections and its development following COVID-19 infection can be attributed to the virus or immune response of the host against it.  Possibility of COVID-19 infection triggering Guillain Barr{\'e} syndrome cannot be ruled out. More studies regarding association of COVID-19 with the neurological disease may help in unraveling the neuro-invasion ability of the virus and to develop measures to prevent it.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}COVID-19,\newline Guillain-Barr{\'e} syndrome,\newline eclampsia,\newline atypical manifestation
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Dibya~Jyoti~Sharma~\\ Phone:\ +91-7637004455~\\  Email:\ dibya.sharma@yahoo.com
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
The novel coronavirus SARS-CoV-2 induced pandemic of COVID-19 pneumonia which originated from Wuhan, China is a highly infective disease with a mean incubation period of 5.2 days and doubling time of case every 7.4 days \unskip~\citep{996876:21350945}. Fever (94\%), cough (79\%), dyspnoea (29\%) were typical symptoms while hypertension (30\%), diabetes (19\%) and coronary artery disease (8\%) were frequent comorbidities detected among patients with COVID-19 \unskip~\citep{996876:21350952}. Not infrequently extra pulmonary manifestations like diarrhea (5\%), vomiting, abdominal pain, elevated liver enzymes, decreased albumin, myocarditis, cardiac arrest, acute coronary syndrome, heart failure, acute kidney injury has been observed \unskip~\citep{996876:21350952,996876:21350960}. COVID-19 can involve both CNS and PNS leading to acute ischemic stroke, cerebral venous sinus thrombosis, decreased consciousness, encephalopathy as well as hypogeusia, hyposmia, neuralgia and peripheral neuropathy \unskip~\citep{996876:21350960,996876:21350946,996876:21350954}. Association of COVID-19 infection with Guillain{\textendash}Barr{\'e} syndrome; an acute polyradiculoneuropathy has also been described in case reports \unskip~\citep{996876:21350949}. We report a case of Guillain{\textendash}Barr{\'e} syndrome in a post partum patient with a history of eclampsia infected with COVID-19. 
    
\section{\textbf{CASE PRESENTATION}}
Our patient was a 27 year old female with a history of eclampsia who presented with abnormal behaviour on the 11\ensuremath{^{th}} day of the postpartum period and was tested positive for COVID-19 on the same day. She had a history of cough, anosmia and ageusia but without a history of fever. She was hospitalized with these indications with a SpO2 of 93\% and was treated with Remdesivir injection, dexamethasone and Enoxaparin injection according to the national COVID protocol for moderate COVID. The patient developed acute flaccid paraparesis on the 5\ensuremath{^{th}} day after hospital admission, which progressed to involve both upper limbs, two days after onset of paraparesis. She had no history of headache, changes in vision or speech, swallowing difficulty, bladder and bowel incontinence, facial deviation, saliva drooling from the angle of the mouth, trauma, sensory symptoms or features of any cranial nerve involvement.

Physical examination findings revealed increased blood pressure (160/90 mmHg) with tachypnoea and tachycardia. Pallor was present along with bilateral pedal edema, which was pitting in character. Her Glasgow Coma Scale was E4V4M2 and nervous system examination revealed areflexia without neck rigidity or Kerning's sign. Muscle power in both lower and both upper limbs were 2/5. Her sensory system examination was normal, with no upper sensory level and without bladder or bowel involvement. Notable laboratory findings included a white cell count of 9,800 x 10\ensuremath{^{9 }} /L, hemoglobin 9.6 gm/dl, MCV 91fl, serum potassium 3.3 mmol/ l, serum sodium 136 mmol/l, serum creatinine 0.42 mg/dl, serum magnesium 1.60 mg/dl, serum TSH 2.34 mIU/L. She was treated with potassium supplementation, magnesium sulphate injection, which corrected her electrolytes. Non-contrast CT scan of the brain revealed normal study, cervical spine and lumbosacral spine X-ray were normal, chest X ray was within normal limit. Cerebrospinal fluid (CSF) sugar was 70 mg/dl, the protein was high (200 mg/dl) and total cell count was normal (2 cells -100\% mononuclear) with normal Adenosine deaminase (ADA) level (7.1 IU/L). The CSF finding was suggestive of albumino-cytological dissociation, which is characteristically detected in Guillain Barr{\'e} Syndrome. Nerve conduction study was not performed as it was not available for an inpatient setting in our hospital.

The patient was treated with standard protocols for COVID-19 and eclampsia and the diagnosis of GBS was made on the basis of CSF study. Methylprednisolone 1gm per day was given for 5 days as plasmapheresis and IV immunoglobulin were not available. She developed type 2 respiratory failure after 7-8 days of hospital admission for which she was intubated and put into volume control mode ventilation. Her repeat RTPCR test for COVID-19 antigen on day 9 came out to be negative and she was shifted out of COVID intensive care unit (ICU) to general ICU. However, the patient developed ventilator associated pneumonia and sepsis for which she was treated with broad spectrum antibiotics and empirical antifungal. In spite of all available standard medical therapy, the patient could not recover from her ailment and she expired on 18\ensuremath{^{th}} day of hospital admission due to progressive respiratory failure.
    
\section{Discussion}
Guillain{\textendash}Barr{\'e} syndrome is the most common cause of acute flaccid paralysis at present which is characterized by areflexia, quadriparesis and albumin-cytological dissociation in cerebrospinal fluid (high protein and normal cell count) with a disability rate of 20\% and a mortality rate of 5\% despite use of immunotherapy\unskip~\citep{996876:21350959} . Guillain{\textendash}Barr{\'e} syndrome is associated with progressive symmetric weakness of bilateral limbs over a period of 12 hrs to 28 days before reaching its nadir and often preceded by pulmonary infection or diarrhea 3 to 6 weeks prior to the onset of disease \unskip~\citep{996876:21350950}. In two third of cases various infectious agents including bacteria and virus has been postulated as causative agent among which \textit{Campylobacter jejuni} (30\%), \textit{Cytomegalovirus} (10\%), \textit{Epstein-Barr virus}, herpes virus and \textit{Mycoplasma pneumoniae } were predominant organism detected. These infective agents induce an autoimmune response due to molecular mimicry of their antigen with the axons and myelin of the peripheral nervous system of the human body \unskip~\citep{996876:21350948}. Autoimmune injury of the peripheral nerves is mediated by deposition of immunoglobulin and complement on the axons and surface of Schwann cells as well as infiltration of nerves by macrophage and T cell. Presence of specific anti ganglioside antibodies in the serum of patients with acute stage of GBS has been linked to the different pattern of clinical features in GBS ranging from only motor nerve involvement to Miller Fisher syndrome \unskip~\citep{996876:21350951}. GBS has shot into the limelight during COVID-19 pandemic as increasing cases of SARS-COV-2 with neurological manifestations has been reported and patients with severe COVID-19 disease were found to have neurological symptoms more frequently \unskip~\citep{996876:21350954}. However, only a few cases of GBS with COVID-19 has been established till date and the first symptoms appear 3 to 24 days after the viral illness similar to the disease interval in our case \unskip~\citep{996876:21350949,996876:21350958}. Most patients with GBS and COVID-19 infection were elderly (mean age57.26 \ensuremath{\pm} 15.82)with slight male preponderance though few cases were reported in children (age range 5-84 year) \unskip~\citep{996876:21350957,996876:21350958}. However, we reported GBS in a young female patient who also had eclampsia simultaneously with COVID-19.

GBS is diagnosed based on clinical features of the acute symmetric weakness of lower limbs, flaccid quadriparesis, facial weakness or root type pain in limbs with cerebrospinal fluid testing showing elevated protein level and normal cell count (albumin cytological dissociation). CSF protein was normal or high with normal cell count in GBS patients associated with COVID-19 as in our case. Nerve conduction velocity (NCV) study showed acute demyelinating polynerupathy (AIDP) in most cases, while axonal neuropathy was observed in a few cases in GBS patients associated with COVID-19 \unskip~\citep{996876:21350949,996876:21350958}. Magnetic resonance imaging (MRI) of spine shows caudal nerve root enhancement or normal reports in patients while antiganglioside antibodies were absent in most patients of GBS with COVID-19 \unskip~\citep{996876:21350949,996876:21350958,996876:21350953}. Polymerase chain reaction assay for SARS-COV-2 was negative in the majority of the patients \unskip~\citep{996876:21350949}. Almost all patients were treated with intravenous immunoglobulin (IVIg) and a few patients COVID-19 associated GBS required ICU admission and mechanical ventilation. The outcome of GBS in COVID-19 was variable ranging from complete recovery to permanent disability in the form of persistence of limb weakness and severe respiratory failure leading to death \unskip~\citep{996876:21350958,996876:21350956,996876:21350953}. GBS in pregnancy is associated with autonomic dysfunction as well as terminal respiratory failure and is a potentially fatal condition. \unskip~\citep{996876:21350947}. However, the postpartum state is associated with an acute motor axonal form of GBS and has a variable but milder course showing complete or partial recovery \unskip~\citep{996876:21350955}. Few reports of GBS is available associated with eclampsia although the incidence of posterior reversible encephalopathy syndrome (PRES) which commonly occurs with eclampsia and septicemia has been rarely encountered with GBS \unskip~\citep{996876:21350944}. The fatal outcome in our case could be explained by the coexistence of multiple risk factors and complications with COVID-19. Clinicians should also consider alternative etiologies like vasculitis, beriberi, porphyria, toxic and critical illness neuropathy before making the diagnosis of GBS. 
    
\section{Conclusion }
Further studies are needed to understand the effect of COVID-19 on the nervous system. Insight regarding the mechanism of GBS following infection with SARS-COV-2 will help improve the outcome of the patients. Prompt diagnosis and treatment of GBS  in the initial stage can prevent potentially serious disability and reduce mortality in patients infected with COVID-19. 

\textbf{Conflict of Interest}

The authors declare that they have no conflict of interest for this study.

\textbf{Funding Support}

The authors declare that they have no funding support for this study.
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
